← Atlas Theme · spans 1 topics
The complete absence of alternative treatments forces the acceptance of severe toxicities in rare-disease approvals.
When evaluating first-in-class therapies for devastating genetic conditions with no approved options, the regulatory framework tolerates substantial safety warnings, hepatotoxicity, and adverse events to establish market access.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
FDA Approves Regeneron's Pasatru, First Treatment to Reduce FOP Flare-Ups and Lesions Regulators approved a highly priced therapy with extensive adverse event risks because the devastating rare disease had zero alternative approved treatments.
Science & Health
FDA Grants Accelerated Approval to Ultragenyx's GENGLYCOS, First-Ever Gene Therapy for GSDIa The FDA approved the first-ever therapy for a rare metabolic disorder despite severe hepatotoxicity warnings and high adverse event rates because no alternative options exist.